Aurinia Pharmaceuticals Inc.

AUPH

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$16.65

−$0.62 · -3.59%

Aug 21, 3:55 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

63/100

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

Deep Value

Momentum

Neutral

Sentiment

Bullish

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CA
CEO: Kevin C. Tang
Listed since: Sep 3, 2014
Employees: 128

Market position

Volume: 1.25M; 0.89× average
Average volume: 1.4M; Average daily volume
Market cap: 2.14B USD
Beta: 1.4; Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 2.14B USD
P/E (TTM): 7.06×
P/B (TTM): 3.52×
P/S (TTM): 6.87×
EV / EBITDA: 16.73×
Earnings yield: 13.40%
Free cash flow yield: 6.32%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 90.36%
Operating margin: 48.39%
Net margin: 100.84%
Return on equity: 49.40%
Return on assets: 38.21%
Return on invested capital: 15.53%

Financial health

Debt / equity: 0.1×
Current ratio: 5.25×

AUPH news

zacks.comAug 20, 2026

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.

Read source

benzinga.comAug 20, 2026

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

Read source

businesswire.comAug 19, 2026

Aurinia Settles Patent Litigation with Teva

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.

Read source

seekingalpha.comAug 12, 2026

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the…

Read source

zacks.comAug 6, 2026

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.

Read source

businesswire.comAug 6, 2026

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress.

Read source